Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 17/20 | 0.36 |
| ▸ | MAOB | P27338 | 8/20 | 0.36 |
| ▸ | MAOA | P21397 | 5/20 | 0.36 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.36 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24267657 | 1.00 | KDM1A (0.36) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Hydrochloric Acid SCHEMBL30556192 | 0.98 | KDM1A (0.38) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL2405510 | 0.87 | ALDH1A1 (0.42) | KDM1AMAOBMAOAALDH1A1HSD17B10 | |
| SCHEMBL19366623 | 0.84 | ALDH1A1 (0.44) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL20907336 | 0.84 | ALDH1A1 (0.44) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL933210 | 0.84 | ALDH1A1 (0.44) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL21422778 | 0.84 | ALDH1A1 (0.44) | KDM1AMAOBMAOAALDH1A1HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL1811903 | 0.82 | ROCK2 (0.34) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL1459410 | 0.81 | ALDH1A1 (0.42) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL9760083 | 0.78 | TTR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504708-A1 | CDK9 INHIBITORS | Biolexis Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240252688-A1 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. | 2024-08-01 | — | — | US | disclosed |
| US-20230416271-A1 | HETEROARYLQUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. (CN) | 2023-12-28 | — | — | US | disclosed |
| WO-2023196517-A1 | CDK9 INHIBITORS | Biolexis Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2022111634-A1 | HETEROARYLQUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | 成都赛璟生物医药科技有限公司 | 2022-06-02 | — | — | WO | disclosed |
| CN-110418789-B | Derivatives of N-cycloalkyl/heterocycloalkyl-4- (imidazo [1,2-a ] pyridine) pyrimidin-2-amines as therapeutic agents | 常州千红生化制药股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| EP-1845973-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2015-08-12 | — | — | EP | disclosed |
| US-9051278-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2015-06-09 | — | — | US | disclosed |
| EP-2256106-B1 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators | ASTEX THERAPEUTICS LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-7385059-B2 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| EP-1845974-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1845975-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1845973-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| US-20060194843-A1 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections; 4-(2,6-difluoro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methyl-piperidin-4-yl)-amide | ASTEX THERAPEUTICS LIMITED (GB) | 2006-08-31 | — | — | US | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| EP-1651612-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | Astex Therapeutics Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194843-A1 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections; 4-(2,6-difluoro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methyl-piperidin-4-yl)-amide | CDK1, CDK3, ROS1 | KDM1A 1922/4885MAOB 3078/4885MAOA 2524/4885 |
| US-20230416271-A1 | HETEROARYLQUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | CDK9, CDK2, CDK6 | KDM1A 1421/4885MAOB 3450/4885MAOA 3566/4885 |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | MKI67, CCNC, CCNI | KDM1A 1594/4885MAOB 2901/4885MAOA 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.